Banque Pictet & Cie’s BioMarin Pharmaceuticals BMRN Stock Holding History

Banque Pictet & Cie’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-57,235	Closed	-$3.1M	–	407
2025 Q3	$3.1M	Buy	+57,235	New	+$3.27M	0.02%	191
2023 Q2	–	Sell	-11,394	Closed	-$1.11M	–	502
2023 Q1	$1.11M	Sell	11,394 -7,336	-39%	-$761K	0.01%	367
2022 Q4	$1.94M	Sell	18,730 -5,020	-21%	-$471K	0.02%	289
2022 Q3	$2.01M	Sell	23,750 -6,157	-21%	-$548K	0.02%	283
2022 Q2	$2.48K	Buy	29,907 +988	+3%	+$78.7K	0.02%	270
2022 Q1	$2.23M	Buy	+28,919	New	+$2.42M	0.02%	314

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Banque Pictet & Cie's BMRN Position: Q4 2025 in Review

Banque Pictet & Cie sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 57,235 shares — an estimated $3.1M sold.

Banque Pictet & Cie first reported a position in BMRN in Q1 2022 and held it in 6 quarters. The position peaked at $3.1M in Q3 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Banque Pictet & Cie reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Banque Pictet & Cie sold 57,235 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $3.1M.
Banque Pictet & Cie first reported a position in BioMarin Pharmaceuticals in Q1 2022 and held it in 6 quarters.
Banque Pictet & Cie's BioMarin Pharmaceuticals position peaked at $3.1M in Q3 2025.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Banque Pictet & Cie's 13F filing for Q4 2025, filed 16 Jan 2026.